PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1629 participants.

Also called NCT03168776

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,629 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03168776
Other papers using this trial's data
  • Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial Circulation, 2021-06 DOI, PubMed 33820424

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Canada, Japan, Netherlands, Spain, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03168776. Randomized; single masking; primary purpose treatment. Start 2017-10-13 (actual); primary completion 2020-10-01 (actual). Results posted on 2026-01-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease
Intervention (Device)
BuMA Supreme DES
Intervention (Device)
Xience or Promus DES
Lead sponsor
Sino Medical Sciences Technology Inc. (class: industry)
Collaborator
Nova Vascular LLC (class: not stated)

Record details

Record id
cardio:ct-nct03168776
Content hash
ccd2c026f88ca5e4217781ac1ad701e274125f0e078cc7f8c8b59eaad80a1d5a